The Neural Metric Factorization for Computational Drug Repositioning

• URL: http://arxiv.org/abs/2109.07690v1
• Date: Thu, 16 Sep 2021 03:14:43 GMT
• Title: The Neural Metric Factorization for Computational Drug Repositioning
• Authors: Xinxing Yang and Genke Yang
• Abstract summary: computational drug repositioning aims to discover new therapeutic diseases for marketed drugs. The matrix factorization model has become a mainstream cornerstone technique for computational drug repositioning. We propose a neural metric factorization model for computational drug repositioning.
• Score: 1.5206182560183663
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Computational drug repositioning aims to discover new therapeutic diseases for marketed drugs and has the advantages of low cost, short development cycle, and high controllability compared to traditional drug development. The matrix factorization model has become a mainstream cornerstone technique for computational drug repositioning due to its ease of implementation and excellent scalability. However, the matrix factorization model uses the inner product operation to represent the association between drugs and diseases, which is lacking in expressive ability. Moreover, the degree of similarity of drugs or diseases could not be implied on their respective latent factor vectors, which is not satisfy the common sense of drug discovery. Therefore, a neural metric factorization model for computational drug repositioning is proposed in this work. We novelly consider the latent factor vector of drugs and diseases as a point in a high-dimensional coordinate system and propose a generalized Euclidean distance to represent the association between drugs and diseases to compensate for the shortcomings of the inner product operation. Furthermore, by embedding multiple drug and disease metrics information into the encoding space of the latent factor vector, the latent factor vectors of similar drugs or diseases are made closer. Finally, we conduct wide analysis experiments on two real datasets to demonstrate the effectiveness of the above improvement points and the superiority of the NMF model.

Related papers

• Large Language Models in Drug Discovery and Development: From Disease Mechanisms to Clinical Trials [49.19897427783105]
  The integration of Large Language Models (LLMs) into the drug discovery and development field marks a significant paradigm shift. We investigate how these advanced computational models can uncover target-disease linkage, interpret complex biomedical data, enhance drug molecule design, predict drug efficacy and safety profiles, and facilitate clinical trial processes.
  arXiv  Detail & Related papers  (2024-09-06T02:03:38Z)
• drGAT: Attention-Guided Gene Assessment of Drug Response Utilizing a Drug-Cell-Gene Heterogeneous Network [9.637695046701493]
  drGAT is a graph deep learning model that can predict sensitivity to drugs. drGAT has superior performance over existing models, achieving 78% accuracy and 76% F1 score for 269 DNA-damaging compounds. Our method can be used to accurately predict sensitivity to drugs and may be useful in the identification of biomarkers relating to the treatment of cancer patients.
  arXiv  Detail & Related papers  (2024-05-14T22:16:52Z)
• Enhancing Acute Kidney Injury Prediction through Integration of Drug Features in Intensive Care Units [0.0]
  The relationship between acute kidney injury (AKI) prediction and nephrotoxic drugs has yet to be explored in the critical care setting. This study proposes a novel approach that leverages patient prescription data as a modality to improve existing models for AKI prediction.
  arXiv  Detail & Related papers  (2024-01-09T05:42:32Z)
• ALNSynergy: a graph convolutional network with multi-representation alignment for drug synergy prediction [8.316187397380244]
  Drug combination refers to the use of two or more drugs to treat a specific disease at the same time. In this work, we propose ALNSynergy, a graph convolutional network with multi-representation alignment for predicting drug synergy.
  arXiv  Detail & Related papers  (2023-11-27T15:34:14Z)
• Emerging Drug Interaction Prediction Enabled by Flow-based Graph Neural Network with Biomedical Network [69.16939798838159]
  We propose EmerGNN, a graph neural network (GNN) that can effectively predict interactions for emerging drugs. EmerGNN learns pairwise representations of drugs by extracting the paths between drug pairs, propagating information from one drug to the other, and incorporating the relevant biomedical concepts on the paths. Overall, EmerGNN has higher accuracy than existing approaches in predicting interactions for emerging drugs and can identify the most relevant information on the biomedical network.
  arXiv  Detail & Related papers  (2023-11-15T06:34:00Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Causal Inference via Nonlinear Variable Decorrelation for Healthcare Applications [60.26261850082012]
  We introduce a novel method with a variable decorrelation regularizer to handle both linear and nonlinear confounding. We employ association rules as new representations using association rule mining based on the original features to increase model interpretability.
  arXiv  Detail & Related papers  (2022-09-29T17:44:14Z)
• Relational graph convolutional networks for predicting blood-brain barrier penetration of drug molecules [12.041672273431994]
  The evaluation of the BBB penetrating ability of drug molecules is a critical step in brain drug development. We employ the relational graph convolutional network (RGCN) to handle the drug-protein relations as well as the features of each individual drug. The performance was already promising, demonstrating the significant role of the drug-protein/drug relations in the prediction of BBB permeability.
  arXiv  Detail & Related papers  (2021-07-04T15:56:02Z)
• Deep Learning for Virtual Screening: Five Reasons to Use ROC Cost Functions [80.12620331438052]
  deep learning has become an important tool for rapid screening of billions of molecules in silico for potential hits containing desired chemical features. Despite its importance, substantial challenges persist in training these models, such as severe class imbalance, high decision thresholds, and lack of ground truth labels in some datasets. We argue in favor of directly optimizing the receiver operating characteristic (ROC) in such cases, due to its robustness to class imbalance.
  arXiv  Detail & Related papers  (2020-06-25T08:46:37Z)
• Hybrid Attentional Memory Network for Computational drug repositioning [0.0]
  The cold start problem has always been a major challenge in the field of computational drug repositioning. We propose the Hybrid Attentional Memory Network (HAMN) model, a deep architecture combines two classes of CF model in a nonlinear manner. Our proposed HAMN model is superior to other comparison models according to the AUC, AUPR and HR indicators.
  arXiv  Detail & Related papers  (2020-06-12T02:12:32Z)
• Ensemble Transfer Learning for the Prediction of Anti-Cancer Drug Response [49.86828302591469]
  In this paper, we apply transfer learning to the prediction of anti-cancer drug response. We apply the classic transfer learning framework that trains a prediction model on the source dataset and refines it on the target dataset. The ensemble transfer learning pipeline is implemented using LightGBM and two deep neural network (DNN) models with different architectures.
  arXiv  Detail & Related papers  (2020-05-13T20:29:48Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.